Disney CEO Speaks on Disneyland Reopening Plans

Walt Disney Co. reopens its two California theme parks on April 30 after they were dark for more than a year, a key step in the entertainment giant’s recovery from the pandemic. CEO Bob Chapek said he’s “thrilled” with future guest reservations. Watch below for more.

 

“I think it’s going to create a reemergence scenario where magic is going to be even greater for our guests when they do come back to our parks.”

Host: What are some of the new technologies that you’ve used over the last year that you think might stick around post pandemic? Will temperature screenings continue? For example, will you use the reservation system a lot more?

Chapek: Well, in addition to all the health guidelines that we’ve been following across the world, you know, masks, temperature checks, increased hygiene, six foot social distancing, we’re also going to be introducing a new reservation system. That’s going to enable our guests to have a great time no matter when they choose to come to Disney. Of course, nobody ever wants to go through a pandemic, but our teams here have been hard at work, making sure that when we reemerge that we’re going to do. So in a way that’s actually going to improve the guest experience even versus a pre pandemic situation. And our guest satisfaction scores, since we’ve reopened across the world, have shown that indeed our guests are even more satisfied than they were prior to the pandemic.

We’ve learned some things. We’ve learned to operate under constraints all the time by delivering this great save Disney magic that you expect. But, you know, we’ve been in a fortunate situation where we’ve had a lot of demand in the past. In many cases, that has exceeded what we can actually supply in terms of how many people we can put in a park. And there’s been no situation that’s been, you know, more like that than we’ve had upon reopening and really having to operate under some really tight constraints. But we’ve gotten even better. And better at it. And I think it’s going to create a reemergence scenario where magic is going to be even greater for our guests when they do come back to our parks.

*Bloomberg contributed to this article

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

 


Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More